Sundry Photography/iStock Editorial via Getty Images
Sundry Photography
- Johnson & Johnson (NYSE:JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets the cardiac disorder atrial fibrillation.
- In reaction, its rivals in the PFA